Search filters

List of works by Roberta Minari

A new variant in signal peptide of the human luteinizing hormone receptor (LHCGR) affects receptor biogenesis causing leydig cell hypoplasia.

scientific article published on 5 August 2015

A novel mutation in the NR0B1 gene in a family with monozygotic twin sisters and congenital adrenal hypoplasia affected children

scientific article published on 01 January 2015

BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall.

scientific article

Concurrent Acquired BRAF V600E Mutation and MET Amplification as Resistance Mechanism of First-Line Osimertinib Treatment in a Patient with EGFR-Mutated NSCLC.

scientific article published on 26 March 2018

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib

scientific article published on 22 December 2020

Evidence for epigenetic abnormalities of the androgen receptor gene in foreskin from children with hypospadias

scientific article published on 21 September 2011

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines

L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR-Mutated NSCLC.

scientific article published on 30 May 2016

L718Q mutant EGFR escapes covalent inhibition by stabilizing a non-reactive conformation of the lung cancer drug osimertinib.

scientific article

Mechanisms of Resistance to Target Therapies in Non-small Cell Lung Cancer

scientific article published on 23 March 2017

Oncogene addiction in non-small cell lung cancer: Focus on ROS1 inhibition

scientific article published on 12 March 2017

Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy

scientific article

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC

Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.

scientific article

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines.

scientific article published on 4 December 2017

Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms.

scientific article

Paulina is supported by:

About Paulina

Help